In a recent report [71], an antibody agonist that targets CMKLR1 was characterized for its ability to induce an anti-inflammatory phenotype of macrophages, with intended therapeutic use in carcinoma progression and inflammatory bowel disease. Here, CMKLR1 is linked to carcinoma.